project id: TCGA-KIRP; case submitter id: TCGA-2Z-A9JK; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.94; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.72; rna integrity number: 9.4; age at index: 50; days to birth: -18540; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1961; age at diagnosis: 18540; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage III; ajcc clinical t: T3a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage III; ajcc pathologic t: T3a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1186.0; icd 10 code: C64.1; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 3.287671232876712; pack years smoked: 60.0; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 829; days to sample procurement: 0; initial weight: 80.0; portion submitter id: TCGA-2Z-A9JK-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 5.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;